The biotech market is experiencing robust growth, fueled by demand for better treatment, personalized medicines, and an increasing number of orphan drug formulations. Further, cutting-edge technology, like AI and supportive government initiatives, are opening wider opportunities for the market.
Given the industry’s shiny prospects, investors could consider watching fundamentally sound biotech stocks MannKind Corporation (MNKD), Amicus Therapeutics, Inc. (FOLD), and Esperion Therapeutics, Inc. (ESPR).
